➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Moodys
AstraZeneca
Express Scripts
Medtronic

Last Updated: June 14, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Rebastinib


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Rebastinib?

Rebastinib is an investigational drug.

There have been 4 clinical trials for Rebastinib. The most recent clinical trial was a Phase 1 trial, which was initiated on September 26th 2018.

The most common disease conditions in clinical trials are Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, and Carcinoma. The leading clinical trial sponsors are Deciphera Pharmaceuticals LLC, Albert Einstein College of Medicine of Yeshiva University, and Montefiore Medical Center.

There are one hundred and sixty-eight US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Rebastinib
TitleSponsorPhase
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid TumorsDeciphera Pharmaceuticals LLCPhase 1/Phase 2
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid TumorsDeciphera Pharmaceuticals LLCPhase 1/Phase 2
Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast CancerAlbert Einstein College of Medicine of Yeshiva UniversityPhase 1

See all Rebastinib clinical trials

Clinical Trial Summary for Rebastinib

Top disease conditions for Rebastinib
Top clinical trial sponsors for Rebastinib

See all Rebastinib clinical trials

US Patents for Rebastinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Rebastinib   Get Started Free ALK and NTRK1 fusion molecules and uses thereof FOUNDATION MEDICINE, INC. (Cambridge, MA)   Get Started Free
Rebastinib   Get Started Free Use of inhibitors of Bruton'S tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA)   Get Started Free
Rebastinib   Get Started Free Use of inhibitors of Bruton's tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Rebastinib

Drugname Country Document Number Estimated Expiration Related US Patent
Rebastinib World Intellectual Property Organization (WIPO) WO2013059740 2031-10-21   Get Started Free
Rebastinib Australia AU2011261185 2030-06-03   Get Started Free
Rebastinib Australia AU2015275321 2030-06-03   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Dow
Merck
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.